Skip to main content
Article thumbnail
Location of Repository

The role of Coenzyme Q10 in statin-associated myopathy

By Dr Sanjay Kalra


Statins, or 3-hydroxyl-3-methylglutaryl coenzyme HMG-CoA reductase inhibitors,\ud are cholesterol-lowering drugs which are frequently used in the primary and secondary\ud prevention of coronary artery disease. Current research and recommendations support\ud and encourage more extensive use of these drugs.\ud However, statin usage is limited by many factors, including a high incidence of\ud statin-associated myalgia and myopathy. This review focuses on the use of Coenzyme Q\ud in statin-associated myopathy

Publisher: Electronic Physician
Year: 2009
OAI identifier:

Suggested articles


  1. (2004). Antioxidant and prooxidant properties of mitochondrial coenzyme Q. Arch Biochem Biophys
  2. (2008). Clinical characterization and molecular mechanisms of statin myopathy. Expert Review of Cardiovascular Therapy
  3. Clinical perspectives of statin –induced rhabdomyolysis. Am Med 19;5:
  4. (2007). Coenzyme Q and statins: Biochemical and clinical implications .Mitochondrion, doi
  5. (2006). Coenzyme Q10 does not improve simvastatin tolerability in dyslipidemic patients with prior statininduced myalgia AHA
  6. Coenzyme Q10 improves myopathic pain in statin treated patients
  7. (2008). Coenzyme Q10: Is there a clinical role and a case for measurement? Clin Biochem Rev
  8. (1997). Comparision of one year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. doi
  9. (2006). Considerations for supplementing with Coenzyme Q10 during statin therapy. The Annals of Pharmacotherapy doi
  10. CoQ10 deficiency diseases in adults. Mitochondrion 2007; 7(Suppl 1):
  11. (2009). Decreased ubiquinone availability and impaired mitochondrial cytochrome oxidase activity associated with statin treatment. Toxicology Mechanisms and Methods
  12. (1999). Distribution of antioxidants among blood components and lipoproteins: significance of lipids/CoQ10 ratio as a possible marker of increased risk for atherosclerosis. doi
  13. dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
  14. Dose-related decreases of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med 1997;18 Suppl:S137- doi
  15. Effect of ezetimibe and /or coenzyme Q10 levels in plasma : a randomized trial. Drug safety 2006; 29(8) doi
  16. (1995). Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts
  17. Effects of diet and simvastatin on serum [Electron. Physician 2009; 1: 2‐8] Page 7 lipids, insulin, and antioxidants in hypercholesterolerolemic men: a randomized controlled trial.
  18. (1993). Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl)
  19. (1999). Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. doi
  20. (1992). Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. Biochim Biophys Acta doi
  21. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. doi
  22. (1994). Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med doi
  23. (1998). HMG CoA reductase inhibitor accelerates aging effect on diaphragm mitochondrial respiratory function in rats Biochem Mol Biol Int
  24. Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs.
  25. Interactions between ascorbyl free radical and coenzyme Q at the plasma membrane.
  26. (1994). Interactions between ubiquinones and vitamins in membranes and cells. Mol Aspects Med
  27. (2005). Muscle coenzyme Q10 level in statinrelated myopathy.
  28. (1998). Myopathy induced by HMGCoA reductase inhibitors in rabbits: a pathological, electro-physiological, and biochemical study. Toxicol Appl Pharmacol
  29. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996;2: 483-491. [Electron. Physician 2009; 1: 2‐8]
  30. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma.
  31. (2007). Reduced mitochondrial coenzyme Q10 levels in Hep G2 cells treated with high –dose simvastatin ; A possible role in statin induced hepatotoxicity ? Toxicology & Applied Pharmacology
  32. Ro 48-8.071, a new 2,3-oxidosqualene: lanosterol cylase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.
  33. (2008). Stalenhoef AF. Effects of ubiquinone (Coenzyme Q10) in myopathy in statin users. Curr Opin Lipidol doi
  34. (1996). The effect of simvastatin treatment on natural antioxidants in lowdensity lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. doi
  35. (2007). The role of coenzyme Q10 in statin-associated myopathy.
  36. Toward ‘pain free’ statin prescribing Clinical algorithm for diagnosis and management of myalgia.
  37. (2005). Treatment of statin adverse effects with supplementation of Coenzyme Q 10 and statin drug discontinuation. BioFactors

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.